Y-mAbs Therapeutics (YMAB) Projected to Post Earnings on Tuesday

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $19.97 million for the quarter. Y-mAbs Therapeutics has set its Q1 2025 guidance at EPS and its FY 2025 guidance at EPS.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. During the same quarter last year, the company earned ($0.02) EPS. On average, analysts expect Y-mAbs Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Y-mAbs Therapeutics Price Performance

Y-mAbs Therapeutics stock traded up $0.30 during mid-day trading on Friday, reaching $4.41. 163,173 shares of the company traded hands, compared to its average volume of 326,063. The firm's fifty day moving average is $4.70 and its two-hundred day moving average is $7.79. The company has a market capitalization of $199.67 million, a price-to-earnings ratio of -8.17 and a beta of 0.53. Y-mAbs Therapeutics has a fifty-two week low of $3.84 and a fifty-two week high of $17.47.

Analyst Ratings Changes

Several research firms recently issued reports on YMAB. Morgan Stanley cut their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research report on Wednesday, March 5th. Wedbush restated an "outperform" rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Truist Financial cut their price target on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Wednesday, March 5th. Bank of America cut shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a research note on Tuesday, April 22nd. Finally, HC Wainwright cut their price objective on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $17.40.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 10,810 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the sale, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. The trade was a 5.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 22.50% of the stock is owned by corporate insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.